Literature DB >> 20717759

Influences of sodium carbonate on physicochemical properties of lansoprazole in designed multiple coating pellets.

Wei He1, Min Yang, Jun Hong Fan, Cai Xia Feng, Su Juan Zhang, Jin Xu Wang, Pei Pei Guan, Wei Wu.   

Abstract

Lansoprazole (LSP), a proton-pump inhibitor, belongs to class II drug. It is especially instable to heat, light, and acidic media, indicating that fabrication of a formulation stabilizing the drug is difficult. The addition of alkaline stabilizer is the most powerful method to protect the drug in solid formulations under detrimental environment. The purpose of the study was to characterize the designed multiple coating pellets of LSP containing an alkaline stabilizer (sodium carbonate) and assess the effect of the stabilizer on the physicochemical properties of the drug. The coated pellets were prepared by layer-layer film coating with a fluid-bed coater. In vitro release and acid-resistance studies were carried out in simulated gastric fluid and simulated intestinal fluid, respectively. Furthermore, the moisture-uptake test was performed to evaluate the influence of sodium carbonate on the drug stability. The results indicate that the drug exists in the amorphous state or small (nanometer size) particles without crystallization even after storage at 40°C/75% for 5 months. The addition of sodium carbonate to the pellet protects the drug from degradation in simulated gastric fluid in a dose-dependent manner. The moisture absorbed into the pellets has a detrimental effect on the drug stability. The extent of drug degradation is directly correlated with the content of moisture absorption. In conclusion, these results suggest that the presence of sodium carbonate influence the physicochemical properties of LSP, and the designed multiple coating pellets enhance the drug stability.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20717759      PMCID: PMC2974110          DOI: 10.1208/s12249-010-9493-x

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  14 in total

1.  Applying the biopharmaceutics classification system to veterinary pharmaceutical products. Part I: biopharmaceutics and formulation considerations.

Authors:  Marilyn Martinez; Larry Augsburger; Thomas Johnston; Wendelyn Warren Jones
Journal:  Adv Drug Deliv Rev       Date:  2002-10-04       Impact factor: 15.470

Review 2.  Recent advances in proton pump inhibitors and management of acid-peptic disorders.

Authors:  Kishor S Jain; Anamik K Shah; Jitender Bariwal; Suhas M Shelke; Amol P Kale; Jayshree R Jagtap; Ashok V Bhosale
Journal:  Bioorg Med Chem       Date:  2006-12-05       Impact factor: 3.641

Review 3.  Microenvironmental pH modulation in solid dosage forms.

Authors:  Sherif I Farag Badawy; Munir A Hussain
Journal:  J Pharm Sci       Date:  2007-05       Impact factor: 3.534

4.  Preformulation investigation of the novel proton pump inhibitor lansoprazole.

Authors:  A Kristl; F Vrecer
Journal:  Drug Dev Ind Pharm       Date:  2000-07       Impact factor: 3.225

Review 5.  The proton-pump inhibitors: similarities and differences.

Authors:  J Horn
Journal:  Clin Ther       Date:  2000-03       Impact factor: 3.393

6.  Properties of solid dispersions of piroxicam in polyvinylpyrrolidone.

Authors:  V Tantishaiyakul; N Kaewnopparat; S Ingkatawornwong
Journal:  Int J Pharm       Date:  1999-04-30       Impact factor: 5.875

7.  Stability and viscosity of a flavored omeprazole oral suspension for pediatric use.

Authors:  Jane E Burnett; Ethan R Balkin
Journal:  Am J Health Syst Pharm       Date:  2006-11-15       Impact factor: 2.637

8.  Properties of enteric coated sodium valproate pellets.

Authors:  L Diane Bruce; Hans-Ulrich Petereit; Thomas Beckert; James W McGinity
Journal:  Int J Pharm       Date:  2003-10-02       Impact factor: 5.875

9.  A novel double-coating approach for improved pH-triggered delivery to the ileo-colonic region of the gastrointestinal tract.

Authors:  Fang Liu; Paloma Moreno; Abdul W Basit
Journal:  Eur J Pharm Biopharm       Date:  2009-11-20       Impact factor: 5.571

10.  Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.

Authors:  Kam Chuen Lai; Shiu Kum Lam; Kent Man Chu; Benjamin C Y Wong; Wai Mo Hui; Wayne H C Hu; George K K Lau; Wai Man Wong; Man Fung Yuen; Annie O O Chan; Ching Lung Lai; John Wong
Journal:  N Engl J Med       Date:  2002-06-27       Impact factor: 91.245

View more
  6 in total

1.  Preparation and evaluation of enteric coated tablets of hot-melt extruded lansoprazole.

Authors:  Bader B Alsulays; Vijay Kulkarni; Sultan M Alshehri; Bjad K Almutairy; Eman A Ashour; Joseph T Morott; Abdullah S Alshetaili; Jun-Bom Park; Roshan V Tiwari; Michael A Repka
Journal:  Drug Dev Ind Pharm       Date:  2016-08-21       Impact factor: 3.225

2.  A Self-microemulsifying Drug Delivery System (SMEDDS) for a Novel Medicative Compound Against Depression: a Preparation and Bioavailability Study in Rats.

Authors:  Lan Wu; Yanli Qiao; Lina Wang; Jiahua Guo; Guocheng Wang; Wei He; Lifang Yin; Jinhua Zhao
Journal:  AAPS PharmSciTech       Date:  2015-02-06       Impact factor: 3.246

3.  Enhanced dissolution and stability of lansoprazole by cyclodextrin inclusion complexation: preparation, characterization, and molecular modeling.

Authors:  Yi Lu; Tao Guo; Jianping Qi; Jiwen Zhang; Wei Wu
Journal:  AAPS PharmSciTech       Date:  2012-09-12       Impact factor: 3.246

4.  Novel lansoprazole-loaded nanoparticles for the treatment of gastric acid secretion-related ulcers: in vitro and in vivo pharmacokinetic pharmacodynamic evaluation.

Authors:  Milind Alai; Wen Jen Lin
Journal:  AAPS J       Date:  2014-02-12       Impact factor: 4.009

5.  Eudragit L/HPMCAS blend enteric-coated lansoprazole pellets: enhanced drug stability and oral bioavailability.

Authors:  Yu Fang; Guozheng Wang; Rong Zhang; Zhihua Liu; Zhenghua Liu; Xiaohui Wu; Deying Cao
Journal:  AAPS PharmSciTech       Date:  2014-03-05       Impact factor: 3.246

6.  A chemotherapeutic approach targeting the acidic tumor microenvironment: combination of a proton pump inhibitor and paclitaxel for statistically optimized nanotherapeutics.

Authors:  Saswati Bhattacharya; Jasmina Khanam; Pradipta Sarkar; Tapan Kumar Pal
Journal:  RSC Adv       Date:  2019-01-02       Impact factor: 4.036

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.